PAR — Paradigm Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$155.77m
- AU$138.96m
- AU$7.11m
- 55
- 16
- 55
- 36
Annual income statement for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | C2022 June 30th | 2023 June 30th | R2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.58 | 7.89 | 8.49 | 6.44 | 7.11 |
| Cost of Revenue | |||||
| Gross Profit | 8.48 | 7.75 | 8.47 | 6.43 | 7.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 43.2 | 48 | 60 | 65.1 | 25.9 |
| Operating Profit | -34.6 | -40.1 | -51.5 | -58.7 | -18.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -34.3 | -39.2 | -51.9 | -58.7 | -18.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.3 | -39.2 | -51.9 | -58.7 | -18.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.3 | -39.2 | -51.9 | -58.7 | -18.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.3 | -39.2 | -51.9 | -58.7 | -18.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.162 | -0.163 | -0.18 | -0.168 | -0.042 |
| Dividends per Share |